{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pubchem:23937",
      "entity_text" : "OS",
      "entity_type" : "simple_chemical"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:387447",
      "entity_text" : "Bortezomib",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Bortezomib produces significant prolongation of OS and TTP compared with standard oral high-dose dexamethasone treatment in patients with relapsed multiple myeloma following 1-3 prior therapies, albeit with an increased incidence of grade 3 adverse events and herpes zoster infections.",
  "reading_complete" : "2020-08-05T22:29:13Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-05T22:25:20Z",
  "trigger" : "produces",
  "evidence" : [ "Bortezomib produces significant prolongation of OS" ],
  "pmc_id" : "3321668",
  "score" : 0
}